{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:40:36Z","timestamp":1767706836546},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,24]],"date-time":"2013-03-24T00:00:00Z","timestamp":1364083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2013,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Hepatitis B reactivation in patients receiving immunosuppressive therapy or chemotherapy may be associated with acute hepatitis, liver failure and\/or death.<\/jats:p><\/jats:sec>Aim<\/jats:title>To audit the efficacy of entecavir as compared to lamivudine for the prophylaxis of HBV<\/jats:styled-content> reactivation in patients with haematological disease receiving immunosuppression or chemotherapy.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients treated for haematological disease with pretreatment serological evidence of chronic hepatitis B (CHB) (HBV surface antigen, HBsAg positive) or resolved HBV infection (HBsAg negative but HBV core antibody positive) are included in this study. Patients received lamivudine 100\u00a0mg or entecavir 0.5\u00a0mg daily. Hepatitis B serology, HBV DNA and ALT were audited at baseline, 6\u00a0months, year 1, 2 and 3. HBV reactivation was defined as a 1 log increase in HBV DNA from baseline or reversion to sA<\/jats:styled-content>g positivity. The occurrence of jaundice, symptomatic hepatitis, liver failure or death were audited.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 40 patients included in the study, 65% (4 CHB<\/jats:styled-content> and 22 resolved HBV<\/jats:styled-content>) received entecavir and 35% (11 CHB<\/jats:styled-content> and 3 resolved HBV<\/jats:styled-content>) received lamivudine. One patient with resolved HBV<\/jats:styled-content> experienced HBV<\/jats:styled-content> seroreversion related to premature cessation of entecavir. Eight patients with CHB<\/jats:styled-content> (two from entecavir group and six from lamivudine group) had detectable HBVDNA<\/jats:styled-content> levels at baseline; one case of HBV<\/jats:styled-content> reactivation related to probable lamivudine resistance was identified. No HBV<\/jats:styled-content> related deaths occurred.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Lamivudine and entecavir are both efficacious in the prophylaxis of hepatitis B reactivation. Entecavir should be used in preference to lamivudine in patients CHB<\/jats:styled-content> with detectable baseline HBV DNA<\/jats:styled-content> levels.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.12154","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T17:25:16Z","timestamp":1362245116000},"page":"1203-1210","source":"Crossref","is-referenced-by-count":39,"title":["Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease"],"prefix":"10.1111","volume":"33","author":[{"given":"Fei W.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Royal North Shore Hospital Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Coyle","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal North Shore Hospital Sydney Australia"},{"name":"Sydney Medical School University of Sydney Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett E.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Royal North Shore Hospital Sydney Australia"},{"name":"Sydney Medical School University of Sydney Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venessa","family":"Pattullo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Royal North Shore Hospital Sydney Australia"},{"name":"Department of Gastroenterology Concord Repatriation and General Hospital Sydney Australia"},{"name":"Sydney Medical School University of Sydney Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00487.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01239.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0331-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21051"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0367-5"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(10)60691-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06243.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.027"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-7-200804010-00008"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22106"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01386.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80024-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22945"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03428.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051287"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07318.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2004.tb00697.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0806-7"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32834da987"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21214"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0528-6"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12154","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T22:39:27Z","timestamp":1696199967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,24]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/liv.12154"],"URL":"https:\/\/doi.org\/10.1111\/liv.12154","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,24]]}}}